VolitionRx Ltd Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)				9 Months Ended
Commitments and Contingencies (Details Narrative)	Aug. 15, 2020 USD ($)	Dec. 13, 2019 USD ($) $ / shares shares	Aug. 07, 2019	Sep. 30, 2020 USD ($)	Sep. 30, 2020 EUR (€)	Sep. 30, 2020 EUR (€)	Dec. 31, 2019 USD ($)
Texas A&M University [Member]
Agreement description				the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest	the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest
Operating Lease Right of Use Obligations [Member]
Weighted average discount rate				4.48%		4.48%
Weighted average remaining lease term				24 months	24 months
Operating lease right-of-use assets and liabilities				$ 257,903			$ 266,101
Payment of lease liabilities				184,796
Operating lease expense				185,077
Short term lease costs				10,737
Managing Director's Agreement [Member]
Total long-term debt				211,028
Stock based compensation expenses				753,000
Amount payable				$ 229
Royality				6.00%	6.00%
Transaction agreement description				In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 Euros payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing.	In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 Euros payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing.
Due to related party				$ 277,794
Novis Animal Solutions LLC [Member]
sales commission	5.00%
consultancy fees	$ 20,000
Potential Equity Interest	2.00%
Novis Animal Solutions LLC [Member] \| Consulting Services Agreement [Member]
Potential Equity Interest			0.05%
1 October 2020 [Member]
Total Collaborative Agreement Obligations				1,960,000
Total long-term debt				2,675,755
Common stock, restricted shares issued in exchange of purchased outstanding shares, value		$ 333,969		73,263
Common stock, restricted shares issued in exchange of purchased outstanding shares, shares \| shares		73,263
Weighted trading price \| $ / shares		$ 4.56
Repayment of debt		$ 350,000		$ 357,000
Holdback period				9 months	9 months
Net liabilities		$ 6,535					$ 55,404
Stock based compensation expenses				$ 165,464
On September 16,2020[Member] \| Bioinformatic Analytics Of Cell Free DNA [Member]
Total long-term debt				64,338
Repayment of long-term loan amount \| €					€ 54,879
In 2019 [Member] \| Taxes A&M University [Member]
Total long-term debt				$ 329,986
Repayment of long-term loan amount \| €					€ 400,000
Loan agreement term				5 years	5 years
In 2019 [Member] \| Biomerica Inc. [Member]
Total long-term debt				$ 54,663
Repayment of long-term loan amount \| €					€ 160,000
In 2019 [Member] \| Namur Invest [Member] \| Loan Agreement [Member] \| Long-term Debt [Member]
Total long-term debt				$ 2,596,172
Repayment of long-term loan amount \| €					€ 500,000
Loan agreement term				4 years	4 years
Principal balance payable				$ 586,189
Maturity date				Sep. 30, 2023	Sep. 30, 2023
In 2018 [Member] \| Long-term Debt [Member] \| Namur Innovation and Growth [Member]
Fixed interest rate on lease				4.00%		4.00%
In 2018 [Member] \| Loan Agreement [Member] \| Long-term Debt [Member] \| Namur Innovation and Growth [Member]
Total long-term debt				$ 317,254
Repayment of long-term loan amount \| €					€ 500,000
Loan agreement term				4 years	4 years
In 2017 [Member] \| Namur Invest [Member] \| Long-term Debt [Member]
Fixed interest rate on lease				0.04%		0.04%
In 2017 [Member] \| Namur Invest [Member] \| Loan Agreement [Member] \| Long-term Debt [Member]
Total long-term debt				$ 102,962
Repayment of long-term loan amount \| €					€ 350,000
Loan agreement term				4 years	4 years
In 2017 [Member] \| SOFINEX [Member] \| Long-term Debt [Member]
Fixed interest rate on lease				4.50%		4.50%
In 2017 [Member] \| SOFINEX [Member] \| Loan Agreement [Member] \| Long-term Debt [Member]
Total long-term debt				$ 1,055,139
Repayment of long-term loan amount \| €					€ 1,000,000
Loan agreement term				7 years	7 years
In 2017 [Member] \| University of Michigan [Member] \| Clinical Study Research Agreement [Member]
Lease agreement expire period				3 years	3 years
Collaborative obligations amount \| €						€ 3,000,000
Collaborative obligations amount due				$ 138,000
In 2017 [Member] \| Munich University [Member] \| Collaborative Research Agreement [Member]
Lease agreement expire period				3 years	3 years
Collaborative obligations amount \| €						€ 360,000
Collaborative obligations amount due				$ 0
In 2016 [Member] \| Namur Invest [Member] \| Long-term Debt [Member]
Fixed interest rate on lease				4.85%		4.85%
In 2016 [Member] \| Namur Invest [Member] \| Loan Agreement [Member] \| Long-term Debt [Member]
Total long-term debt				$ 284,741
Repayment of long-term loan amount \| €					€ 440,000
Loan agreement term				7 years	7 years
In 2016 [Member] \| ING [Member] \| Long-term Debt [Member]
Fixed interest rate on lease				2.62%		2.62%
In 2016 [Member] \| ING [Member] \| Loan Agreement [Member] \| Long-term Debt [Member]
Total long-term debt				$ 249,887
Repayment of long-term loan amount \| €					€ 270,000
Loan agreement term				15 years	15 years
In 2016 [Member] \| DKFZ [Member] \| Research Co-operation Agreement [Member]
Lease agreement expire period				5 years	5 years
Collaborative obligations amount \| €						€ 400,000
Collaborative obligations amount due				$ 234,475
In 2015 [Member] \| Finance Lease Obligations [Member] \| Automated Liquid Handling Robots [Member]
Maturity date				May 31, 2020	May 31, 2020
Amount payable				$ 0
Purchase price for the property \| €						550,454
In 2018 [Member] \| Finance Lease Obligations [Member] \| BNP Paribas leasing solutions [Member]
Maturity date				Jan. 31, 2022	Jan. 31, 2022
Amount payable				$ 13,575
Purchase price for the property \| €						25,000
Leased equipment amortized term				5 years	5 years
In 2018 [Member] \| Walloon Region Government [Member] \| Colorectal Cancer Research Agreement [Member]
Amount payable				$ 212,786
Grant receivable \| €						605,000
Repayment of grants \| €						181,500
Terms of agreement description				it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 Euros and the 3.53% royalty on revenue, is equal to the amount of funding received.	it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 Euros and the 3.53% royalty on revenue, is equal to the amount of funding received.
Total grants repayable				$ 315,259
In 2018 [Member] \| University of Taiwan [Member] \| Clinical Study Research Agreement [Member]
Lease agreement expire period				3 years	3 years
Collaborative obligations amount				$ 2,550,000
Collaborative obligations amount due				$ 892,500
In 2016 [Member] \| Finance Lease Obligations [Member] \| ING Asset Finance Belgium S.A. [Member]
Maturity date				May 31, 2031	May 31, 2031
Amount payable				$ 635,130
Purchase price for the property \| €						1,120,000
In 2010 [Member] \| Walloon Region Government [Member]
Amount payable				$ 102,473
Grant receivable \| €						1,050,000
Repayment of grants \| €						314,406
Terms of agreement description				it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 Euros and the 6% royalty on revenue, is equal to twice the amount of funding received.	it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 Euros and the 6% royalty on revenue, is equal to twice the amount of funding received.
In 2015 [Member] \| DKFZ [Member] \| Research Sponsorship Agreement [Member]
Lease agreement expire period				3 years	3 years
Collaborative obligations amount \| €						€ 338,984
Collaborative obligations amount due				$ 87,928
May 1, 2019 [Member] \| Collaborative Arrangement, Co-promotion [Member]
Collaborative obligations amount due				$ 160,000
Research collaboration agreement description				the Company entered into a research collaboration agreement with the University of Taiwan for a 2-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period	the Company entered into a research collaboration agreement with the University of Taiwan for a 2-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period